Ann: Positive Results from At-Home Sleep Apnoea Study, page-84

The fool is now saying good things. oh how sweet it sounds.
===================

The good news for ResApp shareholders is that for all three AHI thresholds, the area under the receiver operating characteristic curve (AUC) was greater than 0.91. This demonstrates that ResApp’s algorithms, when used at-home, have an excellent ability to identify mild, moderate, or severe OSA.

Interestingly, in a recent ResMed Inc. (ASX: RMD)presentation, it revealed that research shows that less than 20% of those with OSA have been diagnosed or treated. So there certainly could be a large market opportunity for ResApp if it can successfully diagnose people through a smartphone app.

ResApp’s CEO, Tony Keating, was pleased with the results. He said: “We achieved excellent performance previously during our in-laboratory sleep studies and it is great to see the same high levels of performance replicated in our intended use setting, in peoples’ homes.”

Mr Keating also referenced the same data used by ResMed. Adding: “Nearly one billion people suffer from sleep apnoea and 80% of those with moderate or severe sleep apnoea remain undiagnosed. By delivering a highly scalable, low cost smartphone app for OSA screening we have a huge opportunity to reduce the health and economic impact of undiagnosed OSA. We will now move forward into the regulatory submission and commercialisation phases of this exciting project.”

Whilst I think ResApp could be one to watch after this update, I would still buy these exciting growth shares ahead of it at this point.